News · 26 weeks32+14%
2025-12-072026-05-31
Mix2090d
- SEC Filings8(40%)
- Earnings4(20%)
- Insider4(20%)
- Other3(15%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form DEFA14A filed by SenesTech Inc.DEFA14A - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Announces Amendment to Equity Incentive Plan ProposalPHOENIX, June 3, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) ("SenesTech" or the "Company"), today announced that its Board of Directors has approved an amendment to the proposed changes to the Company's 2018 Equity Incentive Plan (the "2018 Plan"), which is being presented for stockholder approval at the Company's 2026 Annual Meeting of Stockholders scheduled for June 9, 2026. As previously disclosed in the Company's definitive Proxy Statement filed on April 29, 2026, stockholders are being asked to approve an amendment to the 2018 Plan to increase the number of shares available for future equity awards. Following furth
- SECSEC Form DEFA14A filed by SenesTech Inc.DEFA14A - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026SURPRISE, Ariz., May 19, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company WebcastThe webcast presentation will take place at 2:30 p.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at http
- INSIDERLarge owner Glenbrook Capital Management bought $53,486 worth of shares (32,120 units at $1.67) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- INSIDERChief Executive Officer Edell Michael bought $5,013 worth of shares (3,000 units at $1.67) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECSenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce TransitionIn-house e-commerce transition and new CEO expected to support scalable recurring revenue growth strategySURPRISE, Ariz., May 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced financial results for the first quarter ended March 31, 2026 and provided an update on the Company's acceleration of revenue under newly appointed Chief Executive Officer, Michael Edell. Q1 2026 Financial HighlightsRevenue increased 2% to $493,
- PRSenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will report financial results for its first quarter 2026, ended March 31, 2026, after the market close on Tuesday, May 12, 2026. The Company has scheduled a conference call that same day, Tuesday, May 12, 2026, at 5:00 pm ET, to review the results. First Quarter
- SECSEC Form DEFA14A filed by SenesTech Inc.DEFA14A - SenesTech, Inc. (0001680378) (Filer)
- SECSenesTech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Appoints Michael Edell as President and Chief Executive Officer to Drive Revenue Growth and Scalable Sales ChannelsSURPRISE, Ariz., May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in humane pest control solutions, today announced the appointment of Michael Edell as President and Chief Executive Officer, effective May 6, 2026. The Company also announced Board leadership transition updates to support SenesTech's next phase of commercial growth and operational execution. Mr. Edell brings a proven track record of building and scaling consumer product businesses, with deep expertise in e-commerce, direct-to-consumer execution, and business
- INSIDERLarge owner Glenbrook Capital Management bought $4,407 worth of shares (3,000 units at $1.47) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECSEC Form DEF 14A filed by SenesTech Inc.DEF 14A - SenesTech, Inc. (0001680378) (Filer)
- SECSEC Form DEFA14A filed by SenesTech Inc.DEFA14A - SenesTech, Inc. (0001680378) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)
- INSIDERLarge owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- SECSenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SenesTech, Inc. (0001680378) (Filer)
- PRSenesTech Announces 2025 Financial Results Driven by Strong Growth in E-CommerceSURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re
- PRSenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa
- INSIDERLarge owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- PRSenesTech Reports Significant Reductions in Rodent Activity Following Evolve® Deployments in Urban Field StudiesSURPRISE, Ariz., Feb. 18, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) ("SenesTech" or the "Company"), a leader in birth control solutions for managing rodent populations, today reported significant reductions in rodent activity following multi-month deployments of Evolve® Rat Birth Control in two urban locations. Results were measured using standardized tracking plate data conducted over a five-month period. Location A – Deployment Initiated April 2025In the first monitored area, where Evolve placement began in April 2025, tracking plate data collected from August 2025 th
- INSIDERLarge owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
- PRSenesTech Strengthens Direct-to-Consumer Commercial Strategy by Directly Managing Amazon Sales of Evolve™ Rat and Evolve™ MouseTransition from Third-Party to Internal Management Expected to Increase Revenue and Enhance Margin on E-Commerce Channel Moving Forward While Building on Early Success PHOENIX, Feb. 10, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) today announced that it will begin directly managing sales of its Evolve™ Rat and Evolve™ Mouse products on Amazon. The change reflects the Company's continued focus on e-commerce as an important distribution channel and will be effective immediately. In 2025, e-commerce represented over 50% of SenesTech's revenue, with about one half of that d
- INSIDERLarge owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)4 - SenesTech, Inc. (0001680378) (Issuer)
SNES FAQ
6 questionsWhat does SenesTech Inc. do?
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait that limits reproduction of male and female rats. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.Where does SNES stock trade?
SenesTech Inc. (SNES) is listed on NASDAQ.What sector and industry is SNES in?
SenesTech Inc. operates in the Industrials sector, Agricultural Chemicals industry.When did SenesTech Inc. go public?
SenesTech Inc. (SNES) completed its IPO in 2016.What companies are similar to SNES?
Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), ICL (ICL Group Ltd.), MOS (Mosaic Company), SMG (Scotts Miracle-Gro Company). Compare SNES side-by-side with any of them on Quantisnow.How can I track SNES on Quantisnow?
Quantisnow aggregates SenesTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNES to receive live email and push alerts on every new disclosure.